期刊
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
卷 26, 期 13, 页码 4659-4665出版社
VERDUCI PUBLISHER
关键词
Skeletal-related events; Bone metastases; Bisphosphonate; Denosumab; Survey
资金
- pharmaceutical company, Amgen
The survey revealed that Italian oncologists tend to use bone-targeted therapy to prevent skeletal-related events in patients with metastatic breast, prostate, or lung cancer, in line with current recommendations.
OBJECTIVE: The Italian Association for Medical Oncology (AIOM) recommends preventive treatment of skeletal-related events in order to improve survival and the quality of life of patients with advanced malignancies. The aim of the study was to evaluate whether routine clinical practice is in agreement with recommendations about the use of denosumab. PATIENTS AND METHODS: A survey was carried out in Italy in the oncological setting. RESULTS: The answers to the survey showed that a large proportion of patients with metastases from solid tumors receive treatment; almost all oncologists administered denosumab every 4 weeks but for a shorter period of time than recommended. CONCLUSIONS: This survey showed that Italian oncologists favor the use of bone-targeted therapy to prevent skeletal-related events in patients affected by metastatic breast. prostate or lung cancer. in agreement with current recommendations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据